Scientists Study How Abivax’s Anti-Inflammatory Product ABX464 Works in IBD

Scientists Study How Abivax’s Anti-Inflammatory Product ABX464 Works in IBD
Researchers have gained new insights into how Abivax’s investigational product ABX464 works. The therapy is currently under investigation in Phase 2 trials in patients with inflammatory bowel disease (IBD). Findings of the study “The Anti-HIV Candidate ABX464 Dampens Intestinal Inflammation by Triggering Il-22 Production in Activated Macrophages” were published in the journal Scientific Reports. “We are

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *